NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Mechanistic Effects of Colchicine in Patients With Myocardial Infarction

Phase 4

Withdrawn

Conditions: Myocardial Infarction

Interventions: Drug: Colchicine 0.6 mg tablets

First Posted Date: 2016-12-16

Last Posted Date: 2019-04-18

Lead Sponsor: NYU Langone Health

Registration Number: NCT02995512

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

Phase 4

Completed

Conditions: Appendicitis

Interventions: Drug: Piperacillin/Tazobactam
Procedure: Surgical Treatment

First Posted Date: 2016-12-14

Last Posted Date: 2022-01-21

Lead Sponsor: NYU Langone Health

Target Recruit Count: 39

Registration Number: NCT02991937

Locations: 🇺🇸
New York University, New York, New York, United States

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 2

Completed

Conditions: Substance Abuse

First Posted Date: 2016-12-08

Last Posted Date: 2019-01-15

Lead Sponsor: NYU Langone Health

Target Recruit Count: 72

Registration Number: NCT02986841

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: DS-8273a
Biological: Nivolumab

First Posted Date: 2016-12-06

Last Posted Date: 2021-10-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 12

Registration Number: NCT02983006

Locations: 🇺🇸
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Phase 2

Withdrawn

Conditions: Glioma

Interventions: Drug: IDH305

First Posted Date: 2016-11-30

Last Posted Date: 2017-12-20

Lead Sponsor: NYU Langone Health

Registration Number: NCT02977689

Locations: 🇺🇸
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York, New York, United States

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1

Completed

Conditions: Addiction

Interventions: Behavioral: Interviews with Stakeholders

First Posted Date: 2016-11-28

Last Posted Date: 2022-08-29

Lead Sponsor: NYU Langone Health

Target Recruit Count: 67

Registration Number: NCT02974335

Locations: 🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Improving Behavioral Health Care for Children With ADHD

Not Applicable

Completed

Conditions: ADHD

Interventions: Behavioral: Behavioral Parent Training (BPT)

First Posted Date: 2016-11-23

Last Posted Date: 2017-09-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 7

Registration Number: NCT02972086

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2016-11-22

Last Posted Date: 2024-04-30

Lead Sponsor: NYU Langone Health

Target Recruit Count: 18

Registration Number: NCT02970981

Locations: 🇺🇸
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States

A New Paradigm for Vitamin D Sufficiency

Not Applicable

Completed

Conditions: New Biomarkers for Measuring Vitamin D Level

Interventions: Other: Placebo
Dietary Supplement: Vitamin D Supplementation
Dietary Supplement: Calcium

First Posted Date: 2016-11-21

Last Posted Date: 2021-10-22

Lead Sponsor: NYU Langone Health

Target Recruit Count: 444

Registration Number: NCT02969850

Locations: 🇺🇸
Winthrop University Hospital, Mineola, New York, United States

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Biological: Avelumab
Radiation: Hypofractionated radiation therapy (HFRT)

First Posted Date: 2016-11-21

Last Posted Date: 2022-06-29

Lead Sponsor: NYU Langone Health

Target Recruit Count: 6

Registration Number: NCT02968940

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York, New York, United States
🇺🇸
UCSF Medical Center, San Francisco, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy